Chronic lymphocytic leukemia (CLL) cells circulating in peripheral blood (PB) differ from the leukemic fraction in lymph nodes (LNs) with respect to cell division and drug sensitivity. CD40 stimulation of PB CLL cells in vitro results in chemoresistance and provides a partial model for the LN microenvironment. The TLR9 ligand CpG induces proliferation in immunoglobulin variable heavychain-unmutated CLL, but apoptosis in immunoglobulin variable heavy-chain-mutated CLL. To juxtapose proliferative with antiapoptotic signals, we investigated the effects of CpG in the context of CD40 ligation in mutated versus unmutated CLL cells in this study. Prolonged CD40 ligation induced classical, followed by alternative nuclear factor-jB (NF-jB), activity in both subgroups, correlating with enhanced Bfl-1 and Bcl-X L levels, respectively. A dichotomy in NF-jB signaling occurred on combined CD40/TLR9 triggering. This induced declining p52 and Bcl-X L levels, and reversed chemoresistance only in mutated cells, whereas unmutated cells proliferated, maintained p52 and Bcl-X L and remained chemoresistant. The pivotal contribution of Bcl-X L to chemoresistance was shown by the BH3 mimetic ABT-737 and RNA interference. Finally, in ex vivo LN samples, p52, p65 and Bcl-X L levels were highly expressed, corroborating the in vitro findings. Thus, a distinction in NF-jB activation and drug susceptibility in mutated versus unmutated (LN-like) CLL cells was uncovered, which was causally linked to Bcl-X L levels.
Introduction
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable (Keating et al., 2003) and prognosis is strongly associated with mutation status of the immunoglobulin variable heavy-chain genes (Fais et al., 1998; Damle et al., 1999; Oscier et al., 2002) . Patients with unmutated CLL have a rapidly progressive disease compared with patients with mutated CLL. Both mutated and unmutated CLL cells show a similar gene expression profile (Klein et al., 2001; Rosenwald et al., 2001 ), but a subset of genes is differentially expressed. Among these genes is the gene encoding the zeta-associated protein of 70 kDa (ZAP70) (Rosenwald et al., 2001) , which is more frequently expressed in unmutated CLL cells. In ZAP70 þ CLL cells, there is enhanced immunoglobulin (Ig)M signaling (Chen et al., 2005) , but the manner in which this affects prognosis is still unclear. It has been speculated that enhanced nuclear factor-kB (NF-kB) signaling in ZAP70 þ CLL cells might have a role in CLL cell survival (Kipps, 2007; Hewamana et al., 2008) . In addition, ligand-receptor interactions, such as CD40L-CD40 (Granziero et al., 2001) , BAFF and APRIL and their various receptors (Endo et al., 2007) , as well as CpG-TLR9 (Decker and Peschel, 2001) , have been studied as inducers of NF-kB activity in CLL. These signaling routes are putative candidates that influence CLL cell survival and thereby the clinical course of the disease.
CpG motifs are present in unmethylated viral and bacterial DNA, but endogenous ligands released during cellular stress are also thought to activate TLR9 receptors (Rifkin et al., 2005) . A dichotomy was observed in peripheral blood (PB) CLL cells from mutated versus unmutated CLL patients stimulated with CpG in vitro (Longo et al., 2007) . CpG stimulation resulted in proliferation in the majority of unmutated CLL cells, whereas mutated CLL cells underwent apoptosis. Notably, PB CLL cells differ in important aspects from the leukemic fraction in lymph node (LN) CLL cells. Although PB CLL cells are prone to apoptosis, sensitive to various drugs and arrested in the G0/G1 phase of the cell cycle, LN CLL cells have an antiapoptotic profile, are supposedly drug resistant and proliferate (Caligaris-Cappio, 2003; Munk and Reed, 2004; Chiorazzi, 2007; Smit et al., 2007) . CD40L stimulation of both mutated and unmutated PB CLL cells in vitro results in an antiapoptotic profile with increased expression of Mcl-1, Bcl-X L and Bfl-1 (Willimott et al., 2007) , and the development of drug resistance (Smit et al., 2007) . However, CD40L stimulation does not induce significant proliferation (Vogler et al., 2008) and thus provides only a partial model for the LN microenvironment.
Two different NF-kB pathways can be distinguished. In the classical pathway, phosphorylation of IkBa leads to degradation of IkBa in the proteasome. As a result, the active NF-kB subunits p65 and p50 translocate to the nucleus and activate their downstream targets (Hayden and Ghosh, 2008) . Alternative NF-kB activation leads to phosphorylation and degradation of p100, which results in translocation of subunits p52 and RelB to the nucleus. Hewamana et al. (2008) showed that in PB CLL cells, the classical NF-kB pathway is associated with in vitro cell survival. It is currently unknown which NF-kB pathway predominates in LN CLL cells, and which possible downstream NF-kB targets, such as Bcl-X L and Bfl-1 (Lee et al., 1999) , are important in causing drug resistance. Second, it is unclear whether mutated and unmutated CLL cells differ in these respects.
To more accurately mimic the in vivo LN microenvironment, in this study, we stimulated mutated and unmutated CLL cells simultaneously with CD40L and CpG. Earlier studies have linked CD40 triggering and NF-kB activity in CLL (Romano et al., 1998; Furman et al., 2000) , but neither the currently recognized clinically important distinction of mutated versus unmutated CLL nor the alternative NF-kB pathway was included in those studies. TLR9 triggering causes Myd88-dependent activation of NF-kB (Klinman, 2004) . Other studies have already reported on the proliferation and cytokine production induced by combined TLR9/CD40 triggering (Decker et al., 2000) . Yet, it is not known whether and to what extent TLR9 signaling interferes with simultaneous CD40 triggering in mutated or unmutated CLL cells to alter NF-kB signaling pathways and development of drug resistance. We performed time course analyses of prolonged CD40L stimulation showing sequential activation of the classical and alternative NF-kB pathway. This correlated with early Bfl-1 and late Bcl-X L upregulation, respectively. Furthermore, a novel distinction in alternative NF-kB activation and drug susceptibility in mutated versus unmutated CLL cells was observed; only in mutated CLL cells combined triggering of CD40 and TLR9 downregulated p52 and Bcl-X L levels and abrogated drug resistance. Finally, in ex vivo CLL LN samples, activation of the classical and alternative NFkB pathway, as well as Bcl-X L expression, could be observed, underlining the relevance of the in vitro observations.
Results
CD40L stimulation of PB CLL cells first activates the classical and then the alternative NF-kB pathway It is assumed that in vivo CLL cells continuously transit from LNs to PB. In LN proliferation centers, CD40-CD40L interaction takes place, which can be mimicked by in vitro coculture of CLL cells from PB on feeder cells expressing human CD40L (Decker et al., 2000; Kater et al., 2004; Smit et al., 2007; Hallaert et al., 2008; Vogler et al., 2008) . The kinetics of CD40L-induced NF-kB activity in such a system is unknown. In time course experiments (0-72 h CD40L stimulation), we found sequential activation of the classical and alternative NF-kB pathway in both mutated and unmutated CLL cells. The classical NF-kB pathway, as detected by phosphorylated IkB, was activated within 1 h (Figure 1a) . Synthesis of p100 and simultaneous appearance of p52 indicating alternative NF-kB pathway activity became apparent from 24-72 h after CD40L stimulation. Bfl-1 and Bcl-X L are members of the antiapoptotic Bcl-2 family and are both downstream NF-kB targets (Lee et al., 1999) . Increased Bfl-1 protein levels were associated with high levels of pIkBa at 6 h of CD40L stimulation, whereas elevated Bcl-X L levels were associated with activation of the alternative NF-kB pathway, as indicated by elevated levels of p52 at 24 h ( Figure 1a) .
To investigate whether Bfl-1 was indeed a downstream target of the classical NF-kB pathway, and Bcl-X L of the alternative pathway, CD40L-stimulated CLL cells were treated with an irreversible inhibitor of IkBa phosphorylation . Blocking classical NF-kB activation resulted in a clear Figure 1 Time course analysis of classical and alternative NF-kB activation and drug resistance in mutated and unmutated CLL cells. (a) Cells were stimulated with CD40L for the indicated times (0, 1, 6, 24 and 72 h). Protein lysates were probed for tIkBa, pIkBa, Bfl-1, p100, p52, Bcl-X L levels, and also for b-actin levels as loading control. Bands were visualized using HRP-conjugated Ig and enhanced chemiluminescence. Blots from one representative mutated and one unmutated patient are shown, of a total of four analyzed for each group. (b) Mutated (n ¼ 4) and unmutated (n ¼ 4) CLL cells were stimulated with 3T3 (control) or CD40L-expressing 3T3 cells for 0, 6 and 72 h with or without classical NF-kB inhibitor BAY-11-7082 (1 mM) as indicated. Protein lysates were probed for pIkBa, Bfl-1, p100, p52 and Bcl-X L , and also for b-actin, which was used as loading control. Western blots were scanned on the Odyssey imager. Blots from a representative mutated and an unmutated patient are shown. (c) Mutated (n ¼ 7) and unmutated (n ¼ 7) cells were cocultured with control 3T3 (control) or CD40L-expressing 3T3 cells for 72 h with or without BAY as indicated. After detachment, cells were incubated with bortezomib for 24 h or fludarabine for 48 h. Apoptosis was measured with MitoTracker staining. Error bars represent standard error of the mean. *0.01oPo0.05. (d) CLL cells were stimulated with 3T3 (control) or CD40L-expressing 3T3 cells for 6, 24 and 72 h. After detachment, cells were incubated with the indicated drugs as described in the Materials and methods section and analyzed for apoptosis by MitoTracker staining after 24 h (bortezomib 30 nM) or 48 h (fludarabine 100 mM). The number of patient samples analyzed was five mutated and six unmutated for the 6 h time point, nine for both groups for the 24 h time point, and eight mutated and six unmutated for the 72 h time point. Error bars represent s.e. of the mean. *0.01oPo0.05; **0.001oPo0.01; ***Po.001. NS, not significant. downregulation of IkBa phosphorylation and Bfl-1 levels. In comparison, p52 and Bcl-X L levels were partially maintained after BAY-11-7082, both in mutated and unmutated CLL cells (Figure 1b) . Thus, alternative NF-kB activation was at least partially independent of classical NF-kB activity in CD40L-stimulated CLL cells.
Prolonged CD40L stimulation of CLL cells is known to induce resistance to various drugs (Romano et al., 1998; Hallaert et al., 2008; Vogler et al., 2008) . Coincubation with BAY-11-7082 did not sensitize mutated and unmutated cells to bortezomib and only partially abrogated the chemoresistance of mutated CD40L-stimulated CLL cells to fludarabine (Figure 1c ). For fludarabine, mutated samples seemed to be more sensitized than unmutated samples, but this did not reach statistical significance (n ¼ 7 for both groups; black bars in Figure 1c ). To further correlate chemoresistance in conjunction with NF-kB activation, we investigated sensitivity of CLL for fludarabine and bortezomib after 6, 24 and 72 h of CD40 stimulation. Significant differences in resistance to bortezomib and fludarabine were observed comparing 6 h of CD40L stimulation with prolonged CD40L stimulation (24 and 72 h) in both patient groups (Figure 1d ). In control samples (medium), no significant differences in apoptosis were observed. Thus, we conclude that the development of CD40L-induced drug resistance occurred predominantly in parallel to enhanced activity of the alternative NF-kB pathway and a rise in Bcl-X L levels.
Combined CD40/TLR9 triggering induces proliferation predominantly in unmutated CLL cells CD40 ligation alone induced proliferation in CLL cells to a very moderate extent ( Figure 2a ) and in a small proportion of cells in cultures for up to 7 days (data not shown). Longo et al. (2007) , have shown that the TLR9 ligand CpG induces proliferation mainly in unmutated CLL cells, whereas mutated CLL cells undergo apoptosis. To more accurately mimic the in vivo LN microenvironment in which CLL cells proliferate, we stimulated CLL cells simultaneously with CD40L and CpG for 3 and 5 days, respectively. As shown before (Longo et al., 2007) , stimulation with CpG only resulted in proliferation of unmutated, but not mutated, CLL cells (Figures 2a and b) . The proliferating fraction on simultaneous CD40/TLR9 triggering was considerably larger than on triggering with either of the stimuli alone. Notably, 3 days of CD40/TLR9 triggering of mutated CLL hardly resulted in proliferation. After 5 days of CD40/TLR9 triggering, a significant difference in proliferation was observed between mutated and In supernatants of these cultures, cytokine levels were determined by enzyme-linked immunosorbent assay. In agreement with previous data (Decker et al., 2000) , secretion of tumor necrosis factor (TNF)-a, interleukin (IL)-6 and also IL-10 was enhanced by combined CD40/TLR9 triggering (Supplementary Figure 1) . For IL-6, IL-8 and IL-10, no differences were observed between mutated and unmutated CLL cells stimulated with CD40L/CpG. Regarding TNF-a levels, there was a trend toward higher levels in the supernatant of unmutated CLL stimulated with CD40L/CpG compared with mutated CLL cells.
Dichotomy in alternative NF-kB activation, Bcl-X L expression and drug susceptibility in mutated versus unmutated CLL cells on combined CD40L and CpG stimulation In view of the above differences, we investigated the effect of CpG on CD40L-induced NF-kB activation and concomitant drug resistance. Western blot analysis was performed for p52, Bcl-X L, pIkBa and Bfl-1 after 72 h of stimulation. Notably, P52 and Bcl-X L showed a clear decline in mutated CLL cells on CD40/TLR9 triggering compared with CD40L stimulation alone. In contrast, in unmutated cells, no such decline in p52 and Bcl-X L was observed (Figure 3a , upper panel). Densitometric
Figure 3 P52 and Bcl-X L levels are downregulated in mutated CLL cells, but not in unmutated CLL cells stimulated with CD40L and CpG. (a) CLL cells were cocultured with control 3T3 (control) or CD40L-expressing 3T3 cells for 72 h with or without CpG as indicated. Protein lysates were probed for p100, p52, Bcl-X L , pIkBa, Bfl-1, as indicated, and for b-actin as loading control. The p52 levels of the unmutated patient depicted were analyzed in two separate western blots of the same experiment, as indicated by the vertical line. Results are representative of at least four different patients. (b) Western blots of p52 and Bcl-X L were quantified using the AIDA image analyzer software in both mutated and unmutated CLL patients stimulated with CpG, CD40L and a combination of CpG and CD40L. Bars represent the average of seven patients ± s.e. P52 and Bcl-X L levels in mutated samples were compared with those in unmutated CLL samples, P ¼ 0.018 and P ¼ 0.007, respectively. *0.01oPo0.05; **0.001oPo0.01. NS, not significant. analysis of seven mutated versus seven unmutated CLL samples revealed that these differences were statistically significant ( Figure 3b) . Compared with the 3T3 control, TLR9 triggering showed a modest upregulation of Bcl-X L in both groups. A representative sample is shown in Figure 3a . There was a trend that unmutated CLL cells (n ¼ 8) stimulated with CD40L/CpG showed higher pIkBa levels than mutated CLL cells (n ¼ 7) stimulated with CD40L/CpG, but this did not reach statistical significance (Supplementary figure 2) . No significant differences in Bfl-1 levels were observed between mutated and unmutated CLL cells stimulated with CD40L/CpG (Figure 3a and Supplementary figure 2) . Thus, a dichotomy occurred in alternative NF-kB signaling and Bcl-X L levels in mutated versus unmutated CLL cells triggered by CD40 and TLR9.
In line with the study by Longo et al. (2007) , CpG induced apoptosis in mutated CLL, and we observed that this could be completely prevented by simultaneous stimulation with CD40L ( Figure 4a ). Next, drug sensitivity to bortezomib and fludarabine was measured in mutated and unmutated CLL cells after 72 h of CD40/TLR9 triggering. In mutated CLL cells, CD40L-induced drug resistance was partially abrogated by adding CpG. In contrast, in unmutated CLL cells, in which CD40L-induced p52 and Bcl-X L levels were unaffected by CpG, no effect on drug resistance was observed (Figure 4a ). For bortezomib and fludarabine, these differences between mutated and unmutated CLL cells were statistically significant (Figure 4b ).
CD40L-induced drug resistance is mediated by Bcl-X L
The previous experiments indicated that Bcl-X L levels are important in the development of drug resistance in CD40L-stimulated CLL cells. To functionally address this, Bcl-X L levels were lowered in two different ways. First, the Bad-like BH3-only mimetic ABT-737, which has high affinity for Bcl-2 and Bcl-X L (van Delft et al., 2006) , was used. Previously, we, along with others, have shown that CLL cells are highly sensitive for ABT-737 and that this is reduced at least 100-fold on CD40 triggering (Hallaert et al., 2008; Vogler et al., 2008) . When used in a sublethal dose in this setting (0.1 mM), ABT-737 significantly increased drug-induced apoptosis in both mutated and unmutated CLL cells stimulated with CD40L/CpG (Figure 5a) .
Next, RNA interference (RNAi) was used to knock down Bcl-X L . Nucleofection with specific small interfering RNA, but not aspecific control small interfering RNA, resulted in a clear knockdown of Bcl-X L (Figure 5b ). Quantified data of the Bcl-X L /b-actin ratio showed significant differences between CLL cells treated with Bcl-X L RNAi and negative control RNAi (Figure 5c ). Importantly, knockdown of Bcl-X L in CLL cells resulted in enhanced drug susceptibility for bortezomib and roscovitine (Figure 5d ). In these experiments, specific apoptosis was calculated and plotted, as background apoptosis was enhanced by the nucleofection procedure. Mean levels of background apoptosis in CD40L-stimulated CLL cells were 25.4 ± 7.78% (mean ± s.e.). For Bcl-X L and negative control RNAi-treated CLL cells, background apoptosis levels were higher (respectively, 43.3±10.53% and 42.3 ± 8.88% (mean ± s.e.)). Fludarabine-induced apoptosis is routinely measured after 48 h after detachment from 3T40L cells, but at this time point background apoptosis levels in Bcl-X L RNAi-treated CLL cells reached B60% and a significant additional effect of fludarabine could not be reliably observed (data not shown). In summary, the combined data from the ABT-737 and RNAi experiments strongly suggested that Bcl-X L levels have an important role in determining drug susceptibility of CLL cells stimulated with CD40L.
PB CLL cells studied in vitro with CD40L and CpG and LN proliferation centers in vivo have a similar NF-kB signaling signature To investigate whether our in vitro model resembled the situation in vivo, LN samples obtained from CLL patients (only available from unmutated patients) were compared with those from PB samples (mutated and unmutated; Figure 6 ). As expected, on the basis of previous studies (Hewamana et al., 2008; Lopez-Guerra et al., 2009) , p65 is present in the nuclei of PB CLL samples, but its levels are significantly higher in LN samples. Bfl-1 could be observed in moderate to high amounts in both PB and LN samples, and there seemed to be no major difference between the two compartments. By comparison, in a control sample using our in vitro CD40L-stimulation system, higher p65 and Bfl-1 levels at 6 and 72 h time points were observed ( Figure 6a ). With regard to the alternative NF-kB pathway, in the majority of LN samples, p100 was clearly processed into p52. In PB samples, activity of the alternative NF-kB pathway was lower, which was correlated with a clear difference in Bcl-X L expression in PB versus LN compartments. In most instances, no p100 band could be observed in ex vivo samples for an unknown reason. The levels of p52 and Bcl-X L were comparable between ex vivo samples and CLL cells stimulated in vitro by CD40L (Figure 6b) . Together, these results strongly suggest that, in the LN compartment, both classical and alternative NF-kB signaling occur, and at appreciably higher levels than in PB. Second, with respect to Bfl-1 and Bcl-X L levels, the alternative pathway seems to predominate in LN, correlating with our in vitro observations. Thus, the in vitro CD40/TLR9 modelwhich renders CLL cells chemoresistant and endows proliferative capacities-at least partially recapitulates the local NF-kB signaling in LN proliferation centers in vivo.
Discussion
In this study, we show that prolonged CD40L stimulation of CLL cells induced sequential classical and alternative NF-kB activation, which correlated with Bfl-1 and Bcl-X L levels, respectively. Combining CD40L and CpG uncovered a dichotomy in prognostic subgroups with respect to proliferation, as well as alternative NF-kB activity, Bcl-X L levels and drug resistance. In addition to the well-known divergent B-cell receptor signaling in ZAP70 þ versus ZAP70À CLL cells (Chen et al., 2005) , this new distinction in survival signaling on CD40L/CpG stimulation may have clinical relevance.
The correlation between CD40L stimulation, NF-kB activity, increased survival and drug resistance in CLL cells has been reported earlier (Romano et al., 1998; Furman et al., 2000) . In addition, a recent study addressed the basal classical NF-kB activity in unstimulated PB CLL cells, which was inversely correlated with the response to fludarabine (Hewamana et al., 2008) . Compared with these studies, our current study provides novel and more detailed information. First, we describe sequential classical and alternative NF-kB signaling in time course experiments, revealing alternative NF-kB activity after prolonged CD40L stimulation. Second, expression of the antiapoptotic Bcl-2 members Bfl-1 and Bcl-X L is shown to be related to classical and alternative NF-kB activation, respectively. Interestingly, induction of Bcl-X L by the alternative NF-kB pathway is related to resistance to various drugs. Third, we separate all our patient data according to the clinically relevant subgroups of mutated (n ¼ 15) versus unmutated (n ¼ 12) CLL cells. Furthermore, using the TLR ligand CpG, we uncover a hitherto undescribed dichotomy in mutated versus unmutated CLL cells, both in relation to proliferation and drug resistance. Finally, by investigating ex vivo LN samples, we show that the relevant signaling pathways and antiapoptotic Bcl-2 family members are active factors in these proliferation centers. It is known that constitutive CD40 signaling in murine B cells induces alternative NF-kB activation and promotes lymphomagenesis (Homig-Holzel et al., 2008) . This correlates well with our finding that prolonged CD40L stimulation of CLL cells (24-72 h) resulted in alternative NF-kB activation and upregulation of Bcl-X L levels. The crucial role of Bcl-X L in the development of drug resistance was shown by the BH3 mimetic ABT-737 and Bcl-X L RNAi.
Simultaneous stimulation with CD40L/CpG has been studied previously in normal and CLL cells to enhance immunogenicity (Decker et al., 2000) . The effect of combined stimulation on drug resistance, or prognostic subgroups and NF-kB signaling, was hitherto unknown. We could show that combined CD40/TLR9 triggering diminished p52 and Bcl-X L levels in mutated CLL cells and partially abrogated drug resistance in mutated, but not unmutated, cells. The reason for the dichotomy in CD40L/CpG induced NF-kB signaling in mutated versus unmutated CLL cells is as yet unknown. It could be related to the well-known difference in ZAP70 expression in mutated and unmutated CLL cells. Indeed, a recent study using unstimulated PB CLL cells reported a relation between ZAP70 status and p65 activity, which determined sensitivity to a novel IkB kinase inhibitor (Lopez-Guerra et al., 2009) . In our setting of in vitro CD40L/CpG stimulation, no changes in ZAP70 expression occurred that could be linked to NF-kB signaling (data not shown). In addition, an earlier report concluded that phospho-IkB correlates with clinical outcome in CLL with LN involvement, but is independent from ZAP70 expression as a prognostic factor of survival (Rodriguez et al., 2004) . We therefore presume that, independent of ZAP70 signaling, the two CLL subgroups might differ intrinsically in their wiring of upstream NF-kB components. It has been shown that both mutated and unmutated CLL cells bear the phenotype of activated B cells (Damle et al., 2002) , but it has been suggested that unmutated CLL cells resemble Figure 6 P52, p65 and Bcl-X L are highly expressed in CLL lymph nodes. (a) Nuclear or cytoplasmic fraction protein lysates obtained from peripheral blood (PB, n ¼ 5) and lymph node (LN, n ¼ 7) were probed for p65, histon H3, Bfl-1 and b-actin as indicated. All lymph node samples were obtained from unmutated CLL patients. The first two PB samples were obtained from mutated CLL patients, the last three samples were obtained from unmutated CLL patients. For comparison, PB CLL cells stimulated in vitro for 6 and 72 h by CD40 were included. (b) Cytoplasmic fractions of the same samples were probed for p100/52, Bcl-X L , and b-actin. We have previously described Bcl-X L levels in lymph node samples (Hallaert et al., 2008) . Western blots were scanned on the Odyssey imager. Vertical lines indicate that images were derived from separate gels.
NF-jB signaling and drug resistance in CLL JM Tromp et al B cells at an earlier state of activation than mutated CLL cells (Pleyer et al., 2009) . The degree to which the premalignant mutated and unmutated CLL cells have been exposed to TNF members, for example, CD40L, BAFF or APRIL, which all affect NF-kB signaling, most likely varies depending on the encounter with T helper cells or by location in the LN (Schneider, 2005; Caligaris-Cappio and Ghia, 2008) . Thus, it is conceivable that different modes of upstream NF-kB signaling are hardwired in the two CLL subgroups. Possibly, in mutated CLL cells stimulated with CD40L/CpG, a negative feedback mechanism is activated, which does not occur in unmutated CLL cells. Negative regulation of NF-kB signaling is mediated by a family of deubiquitinating enzymes, among which are cylindromatosis and A20 (Sun and Ley, 2008) . Recent studies have shown inactivation of A20 in various B-cell malignancies (Compagno et al., 2009; Kato et al., 2009) . Furthermore, alternative NF-kB signaling in many cell types relies on NF-kB-inducing kinase (NIK), which is controlled in a complex manner through interaction with TRAF and IAP family members. Important in the context of our studies, regulation of NIK can be under the control of CD40 or BAFF signaling (Vallabhapurapu et al., 2008; Zarnegar et al., 2008) . If and how CpG/TLR9 signaling interferes with these signaling pathways to affect NF-kB activity, in partcular in the context of CLL, is currently unresolved. However, the source of the dichotomy in mutated versus unmutated CLL cells on CD40/TLR9 triggering might well lie in differential NF-kB signaling mediated through upstream regulators, such as cIAP1/2, A20, NIK and TRAF family members. The complex interplay between these signaling modulators is currently the subject of intense scrutiny (Skaug et al., 2009; Silke and Brink, 2010) . In addition, combined CD40/ TRL9 triggering induces proliferation in unmutated CLL cells, suggesting that these signaling pathways can also interfere or even replace signals that are presumed to initiate from the B-cell receptor. In this context, the recent insights into chronic active B-cell receptor signaling in diffuse large B-cell lymphoma, which also involves constitutive NF-kB activity for cell survival (Davis et al., 2010) , may also have relevance for CLL. On the basis of our current data, Bcl-X L seems to be an important downstream target of the alternative NFkB pathway in determining drug resistance. Treatment with the BH3 mimetic ABT-737, as well as knockdown of Bcl-X L , resulted in enhanced sensitivity to cytotoxic drugs. Treatment with ABT-737 showed complete abrogation of drug resistance in both subgroups. At a concentration of 0.1 mM, ABT-737 treatment by itself did not induce apoptosis, in line with data from Vogler et al. (2008) . In addition, we observed an association between alternative NF-kB activity and Bcl-X L levels. Indeed, specifically blocking classical NF-kB activity by BAY-11-7082 strongly abrogated Bfl-1 expression, whereas only a partial effect on Bcl-X L and p52 expression was observed. Our data indicate that compared with the alternative NF-kB pathway, the classical NF-kB pathway has a minor role in the NF-kB dichotomy of mutated versus unmutated CLL cells stimulated with CD40L/CpG. To date, there are no specific pharmacological inhibitors available to selectively block the alternative NF-kB pathway. NIK RNAi has been used to target the alternative pathway (Tas et al., 2007) , but CD40 requires NIK for signaling events in both the classical and alternative NF-kB pathway (Ramakrishnan et al., 2004) . Thus, NIK might not be the appropriate target to selectively block alternative NF-kB activity on CD40 triggering in CLL.
B-cell receptor triggering is proposed to drive CLL proliferation in vivo, especially for the unmutated subtype (Kipps, 2007) . Various previous studies applied surface IgM crosslinking in vitro to assess [ 3 H] thymidine incorporation (Lankester et al., 1995) or Ki-67 staining (Nedellec et al., 2005) in CLL patients, which resulted in minimal proliferation. By combining CD40L and CpG stimulation, we could show clearly enhanced proliferation in unmutated CLL cells, correlating with the development of drug resistance. By comparison, in mutated CLL cells, CD40L/CpG stimulation resulted in modest proliferation on day 5, and partial abrogation of drug resistance. Although our coculture system provides an oversimplified model for the complex LN microenvironment, various cytokines are produced, such as, TNF-a, APRIL, IL-6, IL-8 and IL-10, which may be involved in tumor cell survival in vivo (Wierda et al., 2003; Ghia et al., 2005; Nishio et al., 2005; Supplementary figure 1 and data not shown) . Finally, the in vitro effects of CD40L/CpG stimulation at least partially relate to the in vivo situation as can be deduced from the comparable, high levels of p52, p65 and Bcl-X L in observed ex vivo CLL LN samples. Our findings also underscore that Bcl-X L is a potential target for therapy, for example, by BH3 mimetics such as ABT-737, especially in unmutated CLL patients.
Currently, CLL is viewed as a heterogeneous malignancy. In a small subset of CLL patients, the disease has a rapid course and requires early treatment. The dynamic cell turnover reported by recent studies (Messmer et al., 2005; van Gent et al., 2008) may well be linked with cell division rates, as well as with the period leukemic cells that reside in LN proliferation centers. Our findings indicate that modeling of the LN characteristics of CLL is feasible and can provide novel information on distinct responses in vitro to cytostatic drugs among prognostic subgroups.
Materials and methods
Patient's material After informed consent, patient's material was obtained during diagnostic or follow-up procedures at the departments of Hematology and Pathology of the Academic Medical Center, Amsterdam. This study was approved by the AMC Ethical Review Board and conducted in agreement with the Helsinki Declaration of 1975, revised in 1983. LN material, diffusely infiltrated by CLL (unmutated), was freshly frozen in liquid nitrogen directly after surgical removal. Immunohistochemical analysis of LN revealed that greater than 90% of the tissue consisted of tumor cells (Smit et al., 2007) . PB cells of patients with CLL, obtained after Ficoll density gradient centrifugation (Pharmacia Biotech, Roosendaal, The Netherlands), were frozen and stored as described (Hallaert et al., 2008 Cell culture, proliferation assay and detection of apoptosis PB lymphocytes of CLL patients were stimulated by coculture with NIH3T3 fibroblasts stably transfected with human CD40L, as previously described (Hallaert et al., 2008) . Briefly, dimethyl sulfoxide-frozen CLL cells were thawed and cocultured on irradiated (30 Gy) control NIH3T3 fibroblasts or on NIH3T3 fibroblasts expressing CD40L ± CpG (1.5 mg/ml). The CLL-cell concentration was 1.67 Â 10 6 cells/ml in Iscove's modified Dulbecco's medium containing 10% fetal calf serum. After 1, 6, 24 or 72 h of culture at 37 1C, cells were detached and incubated in medium with or without cytotoxic drugs for an additional 24-48 h. To test the effect of BAY-11-7082, cells were pretreated for 30 min with 1 mM of To analyze proliferation on CD40L/CpG stimulation, CLL cells were labelled with carboxyfluorescein diacetate succinimidyl ester (Molecular Probes, Leiden, The Netherlands). Cells were resuspended in PBS at 1.0 Â 10 7 /ml in 0.5 mM carboxyfluorescein diacetate succinimidyl ester for 15 min at 37 1C and washed. After stimulation for 72 h with CD40L/CpG, cells were analyzed by flow cytometry.
For apoptosis induction, cells were treated with 100 mM fludarabine (48 h), 30 nM bortezomib (24 h) or 25 mM roscovitine (24 h), and stained with 200 nM MitoTracker Orange (Molecular Probes) for 30 min at 37 1C followed by flow cytometry (Hallaert et al., 2008) . In addition, apoptotic and viable cells were discriminated by Annexin V (IQ Products, Groningen, The Netherlands) and propidium iodine staining (Sigma Chemical Co.) as described (Hallaert et al., 2008) .
Western blot and antibodies
Western blotting was performed as previously described (Hallaert et al., 2008) . Samples (10-80 mg protein) were separated by 13% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Blots were probed with polyclonal anti-Bcl-X L (catalog no. 620211, BD Biosciences), antiserum to b-actin (clone I-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal NF-kB2 p100/p52 (catalog no. 4882, Cell Signaling), polyclonal anti-total IkBa (catalog no. 9242, Cell Signaling), monoclonal mouse antibody for phopho-IkBa (catalog no. 9246, Cell Signaling), polyclonal anti-p65 (clone C-20; catalog no. sc-372; Santa Cruz) and polyclonal antihiston H3 (catalog no. 9715 Cell Signaling), and also with polyclonal antibodies against A1/Bfl-1, which were a kind gift from Professor Dr Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands). Immunoreactive proteins were visualized using HRP-conjugated Ig (DAKO, Glostrup, Denmark) and enhanced chemiluminescence (ECL, Amersham, Buckinghamshire, UK). IRDye 680 donkey anti-rabbit IgG, IRDye 800 donkey anti-goat IgG or IRDye 800 donkey antimouse IgG (Westburg, Leusden, The Netherlands) was used as secondary antibody when blots were scanned on the Odyssey imager (LI-COR Biosciences, Lincoln, NE, USA). When indicated, western blots were subjected to densitometry by analysis with the AIDA image analyzer software (AIDA Image Analyzer version 3.52, LI-COR Biosciences) or the Odyssey software (Odyssey Application software version 3.0, LI-COR Biosciences).
Enzyme-linked immunosorbent assay IL-6, IL-8, IL-10 and TNF-a in supernatants were measured using the PeliKine human enzyme-linked immunosorbent assay kit (Sanquin, Amsterdam, The Netherlands) according to the manufacturer's instructions. Absorbance was read at 450 nm.
RNAi and nucleofection CLL cells were transfected using the Amaxa nucleofection technology (Amaxa, Koln, Germany), according to the manufacturer's instructions and as described (Vogler et al., 2008) . Briefly, cells (5.0 Â 10 6 ) were resuspended in 100 ml human B-Cell nucleofector kit solution (Amaxa). RNAi (Bcl-X L and Silencer Select Negative Control no. 1) was obtained from Ambion (ID no. 1920 and Catalog no. 4390843 ) and 1.5-3 mg was used. Cell suspensions mixed with RNAi were nucleofected with the Amaxa Nucleofector apparatus using program X-05. Thereafter, cells were immediately transferred into a prewarmed six-well plate containing NIH3T3 cells expressing CD40L, and cocultured for 72 h before protein lysates were obtained and treatment with cytotoxic drugs was initiated.
Statistics
The Shapiro-Wilk normality test was conducted to analyze Gaussian distributions. If there was a Gaussian distribution, a two-sided t-test was used to analyze differences between groups. If there was no Gaussian distribution, a two-tailed Mann-Whitney U-test was used to analyze differences between the groups and a Wilcoxon matched paired test to analyze differences between paired samples. Statistical significance was set at Po0.05, with *representing 0.01oPo0.05; **0.001oPo0.01; ***Po0.001.
